Reaction
Tendon Injury reporting signals
As of the last recalculation, Tendon Injury appears in 3,687 FAERS reports alongside 25 co-occurring drug terms. The strongest observed disproportionality signal is CIPROFLOXACIN (PRR 22.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ciprofloxacin | 329 | 22.1 | 22.2 |
| Ciprofloxacin Hydrochloride | 341 | 21.7 | 21.8 |
| Ciprofolxacin | 257 | 21.7 | 21.8 |
| Ciprofloxacin Tablets | 257 | 21.7 | 21.8 |
| Ciprofloxacin Hydrochloride And Hydrocortisone | 73 | 20.2 | 20.3 |
| Sucralfate Oral | 29 | 11.6 | 11.6 |
| Sucralfate Oral Suspension | 29 | 11.6 | 11.6 |
| Levofloxacin | 111 | 10.7 | 10.7 |
| Levofloxacin In 5% Dextrose | 111 | 10.7 | 10.7 |
| Sucralfate | 31 | 7.4 | 7.4 |
| Methylprednisolone Acetate | 9 | 6.4 | 6.4 |
| Meloxicam | 49 | 4.8 | 4.8 |
| Rizatriptan Benzoate | 8 | 4.4 | 4.4 |
| Testosterone | 17 | 4.1 | 4.1 |
| Sodium Oxybate | 39 | 3.4 | 3.4 |
| Adalimumab | 343 | 2.9 | 2.9 |
| Asfotase Alfa | 5 | 2.8 | 2.8 |
| Insulin Degludec | 11 | 2.7 | 2.7 |
| Upadacitinib | 37 | 2.6 | 2.6 |
| Prasugrel Hydrochloride | 4 | 2.2 | 2.2 |
| Secukinumab | 60 | 2.1 | 2.1 |
| Teriparatide | 42 | 2.1 | 2.1 |
| Avapritinib | 4 | 1.9 | 1.9 |
| Lifitegrast | 5 | 1.7 | 1.7 |
| Evolocumab | 20 | 0.7 | 0.7 |